Shigellosis Treatment & Management
- Author: Joyann A Kroser, MD, FACP, FACG, AGAF; Chief Editor: BS Anand, MD more...
General supportive care of patients with shigellosis includes the following:
- High fever in children should be treated.
- Narcotic-related antidiarrheals should be avoided.
- Antibiotic treatment is indicated in most patients.
Antimotility agents should be avoided. They have the potential to worsen symptoms and may predispose to toxic dilation of the colon.
For fluid and electrolyte supplementation, oral rehydration solutions are preferable.
Educate patients about proper hygiene. Careful handwashing and stool precautions should prevent the dissemination of shigellosis.
Consult a gastroenterologist or an infectious diseases expert if the Shigella infection is prolonged or if the patient experiences a severe course of shigellosis that is unresponsive to antibiotics.
Clear liquids followed by a low residue, lactose-free diet are recommended until symptoms of shigellosis resolve.
A vaccine for shigellosis is not currently available. Until a vaccine is available, the following measures can help prevent the dissemination of shigellosis:
- Use of safe drinking water
- Chlorination of unreliable water sources
- Strict handwashing
- Refrigeration and proper preparation and cooking of food. Food handlers must be treated with antibiotics and should not be involved in food preparation as long as stool cultures are positive for Shigella infection. At least 48 hours of antibiotic treatment are usually required.
Mellouk N, Enninga J. Cytosolic access of intracellular bacterial pathogens: the Shigella paradigm. Front Cell Infect Microbiol. 2016. 6:35. [Medline].
Killackey SA, Sorbara MT, Girardin SE. Cellular aspects of Shigella pathogenesis: focus on the manipulation of host cell processes. Front Cell Infect Microbiol. 2016. 6:38. [Medline].
Agaisse H. Molecular and cellular mechanisms of Shigella flexneri dissemination. Front Cell Infect Microbiol. 2016. 6:29. [Medline].
Nuesch-Inderbinen M, Heini N, Zurfluh K, Althaus D, Hachler H, Stephan R. Shigella antimicrobial drug resistance mechanisms, 2004-2014. Emerg Infect Dis. 2016 Jun. 22 (6):1083-5. [Medline].
Dupont HL, Edelman R, Kimmey M. Infectious diarrhea: from E coli to Vibrio. Patient Care. 1990. 30:18-43.
Al-Abri SS, Beeching NJ, Nye FJ. Traveller's diarrhoea. Lancet Infect Dis. 2005 Jun. 5(6):349-60. [Medline].
Moralez EI, Lofland D. Shigellosis with resultant septic shock and renal failure. Clin Lab Sci. 2011 Summer. 24(3):147-52. [Medline].
Khan WA, Griffiths JK, Bennish ML. Gastrointestinal and extra-intestinal manifestations of childhood shigellosis in a region where all four species of Shigella are endemic. PLoS One. 2013. 8(5):e64097. [Medline].
Khan WA, Griffiths JK, Bennish ML. Gastrointestinal and extra-intestinal manifestations of childhood shigellosis in a region where all four species of Shigella are endemic. PLoS One. 2013. 8(5):e64097. [Medline]. [Full Text].
Bennish ML. Potentially lethal complications of shigellosis. Rev Infect Dis. 1991 Mar-Apr. 13 Suppl 4:S319-24. [Medline].
Bennish ML, Azad AK, Yousefzadeh D. Intestinal obstruction during shigellosis: incidence, clinical features, risk factors, and outcome. Gastroenterology. 1991 Sep. 101(3):626-34. [Medline].
Azad MA, Islam M, Butler T. Colonic perforation in Shigella dysenteriae 1 infection. Pediatr Infect Dis. 1986 Jan-Feb. 5(1):103-4. [Medline].
Martin T, Habbick BF, Nyssen J. Shigellosis with bacteremia: a report of two cases and a review of the literature. Pediatr Infect Dis. 1983 Jan-Feb. 2(1):21-6. [Medline].
Struelens MJ, Patte D, Kabir I, Salam A, Nath SK, Butler T. Shigella septicemia: prevalence, presentation, risk factors, and outcome. J Infect Dis. 1985 Oct. 152(4):784-90. [Medline].
Morduchowicz G, Huminer D, Siegman-Igra Y, Drucker M, Block CS, Pitlik SD. Shigella bacteremia in adults. A report of five cases and review of the literature. Arch Intern Med. 1987 Nov. 147(11):2034-7. [Medline].
Keddy KH, Sooka A, Crowther-Gibson P, et al. Systemic shigellosis in South Africa. Clin Infect Dis. 2012 May. 54(10):1448-54. [Medline].
Keusch GT, Bennish ML. Shigellosis: recent progress, persisting problems and research issues. Pediatr Infect Dis J. 1989 Oct. 8(10):713-9. [Medline].
Butler T, Islam MR, Bardhan PK. The leukemoid reaction in shigellosis. Am J Dis Child. 1984 Feb. 138(2):162-5. [Medline].
Khan WA, Dhar U, Salam MA, Griffiths JK, Rand W, Bennish ML. Central nervous system manifestations of childhood shigellosis: prevalence, risk factors, and outcome. Pediatrics. 1999 Feb. 103(2):E18. [Medline].
Avital A, Maayan C, Goitein KJ. Incidence of convulsions and encephalopathy in childhood Shigella infections. Survey of 117 hospitalized patients. Clin Pediatr (Phila). 1982 Nov. 21(11):645-8. [Medline].
Simon DG, Kaslow RA, Rosenbaum J, Kaye RL, Calin A. Reiter's syndrome following epidemic shigellosis. J Rheumatol. 1981 Nov-Dec. 8(6):969-73. [Medline].
Siegler RL. The hemolytic uremic syndrome. Pediatr Clin North Am. 1995 Dec. 42(6):1505-29. [Medline].
Murphy TV, Nelson JD. Shigella vaginitis: report of 38 patients and review of the literature. Pediatrics. 1979 Apr. 63(4):511-6. [Medline].
Tobias JD, Starke JR, Tosi MF. Shigella keratitis: a report of two cases and a review of the literature. Pediatr Infect Dis J. 1987 Jan. 6(1):79-81. [Medline].
Rubenstein JS, Noah ZL, Zales VR, Shulman ST. Acute myocarditis associated with Shigella sonnei gastroenteritis. J Pediatr. 1993 Jan. 122(1):82-4. [Medline].
Kroser JA, Metz DC. Evaluation of the adult patient with diarrhea. Prim Care. 1996 Sep. 23(3):629-47. [Medline].
Banerjee S, LaMont JT. Treatment of gastrointestinal infections. Gastroenterology. 2000 Feb. 118(2 Suppl 1):S48-67. [Medline].
Murphy GS, Bodhidatta L, Echeverria P, et al. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann Intern Med. 1993 Apr 15. 118(8):582-6. [Medline].
Wolf DC, Gianella RA. Invasive pathogens. Consultations in Gastroenterology. 1996. 381-384.
Sivapalasingam S, Nelson JM, Joyce K, et al. High prevalence of antimicrobial resistance among Shigella isolates in the United States tested by the National Antimicrobial Resistance Monitoring System from 1999 to 2002. Antimicrob Agents Chemother. 2006 Jan. 50(1):49-54. [Medline].
Vinh H, Anh VT, Anh ND, Campbell JI, Hoang NV, Nga TV, et al. A multi-center randomized trial to assess the efficacy of gatifloxacin versus ciprofloxacin for the treatment of shigellosis in Vietnamese children. PLoS Negl Trop Dis. 2011 Aug. 5(8):e1264. [Medline]. [Full Text].
Policar M. Shigellosis. Ferri's Clinical Advisor: Instant Diagnosis and Treatment. 2005. 752-754.
Taneja N. Changing epidemiology of shigellosis and emergence of ciprofloxacin-resistant Shigellae in India. J Clin Microbiol. 2007 Feb. 45(2):678-9. [Medline].
Heiman KE, Karlsson M, Grass J, Howie B, Kirkcaldy RD, Mahon B, et al. Notes from the field: Shigella with decreased susceptibility to azithromycin among men who have sex with men - United States, 2002-2013. MMWR Morb Mortal Wkly Rep. 2014 Feb 14. 63(6):132-3. [Medline].
Lewis R. Azithromycin Not Effective Against All Shigella Infections. Available at http://www.medscape.com/viewarticle/820607. Accessed: February 23, 2014.
Lübbert C. Antimicrobial therapy of acute diarrhoea: a clinical review. Expert Rev Anti Infect Ther. 2016. 14 (2):193-206. [Medline].
Li YL, Tewari D, Yealy CC, Fardig D, M'ikanatha NM. Surveillance for travel and domestically acquired multidrug-resistant human Shigella infections-Pennsylvania, 2006-2014. Health Secur. 2016 May-Jun. 14 (3):143-51. [Medline].